Here's a look at some of the top Wall Street stories for medical device companies this week.
, American College of Cardiology
, Arterial Remodeling Technologies
, Baxter International
, Edwards Lifesciences
, K-C Health Care
, Kimberly-Clark Worldwide Inc.
, Smith & Nephew
, Urologix Inc.
Baxter International says it plans to go the way of rivals Abbott and Covidien in splitting its pharmaceuticals and medical products businesses into separate companies.
Abbott's 4th-quarter and 2013 earnings per share meet expectations on Wall Street, but another revenue miss pushes shares down today.
An anonymous source tells Bloomberg Businessweek that Abbott pharmaceutical spin-off AbbVie will fire its cardiology drugs salesforce amid growing competition from generics.
Medical products giant Abbott Laboratories details its operations in the final months before spinning out its research pharmaceuticals division, with 1-time expenses dragging down its bottom line.
Medical products giant Abbott (NYSE:ABT) took a hit to its bottom line in the final quarter of 2012, with profits dropping by more than ⅓ as the company prepared for an overhaul.
Healthcare giant Abbott starts off its post-split season with an FDA win for its Xience Xpedition drug-eluting stent system.
Abbott (NYSE:ABT) announced FDA approval for its Xience Xpedition coronary stent, planning commercial launch in the U.S. immediately.
Abbott's Xience line of drug-eluting stents are the only such devices on the U.S. market approved for "direct stenting," in which the stent is delivered to the targeted blood vessel without a prior procedure preparing the lesion.
Healthcare giant Abbott will split into 2 parts starting tomorrow, separating its proprietary drug division from the generics, diagnostics, devices and nutrition arm.
MASSDEVICE ON CALL — Healthcare giant Abbott (NYSE:ABT) will officially split into 2 parts starting tomorrow, essentially separating the proprietary drug division from the rest of the company.